NRx Pharmaceuticals to Participate in H.C. Wainwright's 27th Annual Global Investment Conference

NRx Pharmaceuticals CEO Jonathan Javitt will participate in a fireside chat at H.C. Wainwright's 27th Annual Global Investment Conference on September 8, 2025. A webcast will be available on the company's website. Management will also participate in one-on-one investor meetings. The company is developing therapeutics for central nervous system disorders, including suicidal depression, chronic pain, and PTSD.

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) has announced that CEO Jonathan Javitt will participate in a fireside chat at H.C. Wainwright's 27th Annual Global Investment Conference on September 8, 2025. The event will be webcast on the company's website, and management will also be available for one-on-one investor meetings.

The conference comes at a critical time for NRx Pharmaceuticals, which is developing therapeutics for central nervous system disorders, including suicidal depression, chronic pain, and PTSD. The company has made significant strides in its pipeline, with NRX-101, an FDA-designated investigational Breakthrough Therapy, showing promise for suicidal treatment-resistant bipolar depression.

NRx Pharmaceuticals recently filed for a new Commissioner's National Priority Voucher (CNPV) for NRX-100, a preservative-free IV ketamine formulation. The company also filed an Abbreviated New Drug Application (ANDA) for NRX-100 for use in ketamine's currently approved indications. Furthermore, NRx has initiated a New Drug Application filing for NRX-100 for the treatment of suicidal depression, based on results from clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities.

The fireside chat with Jonathan Javitt will provide investors with an opportunity to gain insights into the company's pipeline, strategic initiatives, and future prospects. The webcast and one-on-one investor meetings will offer a chance to ask questions directly to the management team and learn more about NRx Pharmaceuticals' progress in the development of innovative therapies for central nervous system disorders.

References:
[1] https://investorshub.advfn.com/NRX-Pharmaceuticals-Inc-NRXP-38787
[2] https://finance.yahoo.com/news/ibn-coverage-nrx-pharmaceuticals-nasdaq-190000460.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr